This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Damle, B.
Right arrow Articles by Dowell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damle, B.
Right arrow Articles by Dowell, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2673-2676, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01596-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics and Tissue Distribution of Anidulafungin in Rats {triangledown}

Bharat Damle,1* Martin Stogniew,2 and James Dowell2

Pfizer Inc., New York, New York 10017,1 Vicuron Pharmaceuticals, New York, New York2

Received 11 December 2007/ Returned for modification 5 February 2008/ Accepted 16 April 2008

This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 min, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma.

* Corresponding author. Mailing address: Clinical Pharmacology, Pfizer Global Research and Development, 685 3rd Avenue, New York, NY 10017. Phone: (212) 733-4739. Fax: (646) 441-4493. E-mail: bharat.damle{at}pfizer.com

{triangledown} Published ahead of print on 28 April 2008.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2673-2676, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01596-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • VandenBussche, H. L, Van Loo, D. A (2010). A Clinical Review of Echinocandins in Pediatric Patients. The Annals of Pharmacotherapy 44: 166-177 [Abstract] [Full Text]  
  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Damle, B. D., Dowell, J. A., Walsky, R. L., Weber, G. L., Stogniew, M., Inskeep, P. B. (2009). In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin. Antimicrob. Agents Chemother. 53: 1149-1156 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»